Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+ B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study.

Scientific Reports
Bo JiangLugui Qiu

Abstract

This multicenter, randomized, double-blind, parallel-controlled trial aimed to compare the pharmacokinetics (PK) of IBI301 with rituximab in patients with CD20-positive (CD20+) B-cell lymphoma, who achieved a complete response/unconfirmed complete response after standard treatments. Patients were randomized (1:1) to receive IBI301 or rituximab (375 mg/m2, IV). Patients who continuously benefitted from the trial after the PK phase underwent the extension phase to receive up to three cycles of 3-month-cycle of rituximab/IBI301 maintenance therapy. PK was described using the area under the serum concentration-time curve from time zero to infinity (AUC0-inf), AUC from time zero to last quantifiable concentration (AUC0-t), and maximum serum concentration (Cmax). Pharmacodynamics (PD), incidence of adverse events and immunogenicity were evaluated. PK was defined equivalent, if 90% confidence intervals (CIs) for geometric mean ratios of PK endpoints fell within the margin of 0.8-1.25. Overall, 181 patients were enrolled in IBI301 (n = 89) and rituximab (n = 92) groups. Geometric mean ratios of AUC0-inf, AUC0-t, and Cmax were 0.91 (90% CI 0.85, 0.97), 0.91 (90% CI 0.86, 0.97), and 0.96 (90% CI 0.92, 1.01) between treatment groups, all ...Continue Reading

References

Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Apr 29, 2009·Biometrics·Song Yang, Ross Prentice
Mar 8, 2013·Annals of the Rheumatic Diseases·Polina PutrikUNKNOWN Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’
Feb 25, 2014·Seminars in Oncology·Lynne A Bui, Carrie Taylor
Jun 11, 2015·Seminars in Arthritis and Rheumatism·Rieke Alten, Bruce N Cronstein
Apr 8, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Hector A CuelloMariano R Gabri
Jun 23, 2016·Cancer Chemotherapy and Pharmacology·Vikram GotaHari Menon
Jul 22, 2016·The Oncologist·Emilie M J van BrummelenJan H M Schellens
May 30, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Masahiro YokoyamaKiyohiko Hatake
May 17, 2018·Arthritis·Maria GreenwaldK Lea Sewell
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Mar 19, 2019·Journal of Blood Medicine·Raihan MohammedUtkarsh Ojha
Apr 4, 2019·Current Oncology Reports·Rachel HuBrian T Hill
Aug 26, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Soohyun LeeEunYoung Kim
Feb 18, 2020·Therapeutic Advances in Hematology·Peter A Riedell, Michael R Bishop

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay

Clinical Trials Mentioned

NCT02945215

Software Mentioned

SAS

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.